TECHNICAL ADVANCES AND LONG-TERM RESULTS OF PERIACETABULAR OSTEOTOMY.

Abstract

Purpose of the study: Acetabular dysplasia is a recognized cause of premature hip degeneration. With increasing use of arthroplasty, the role of conservative treatment can be debated. The purpose of this work was to describe technical advances achieved with Ganz triple periacetabular osteotomy and evaluate long-term results.

Material and methods: This study included 32 dysplastic hips in 28 patients treated by Ganz triple osteotomy and assessed a mean 12 years follow-up (range 2 – 20 years). Mean age was 32 years (range 18–47). There were 24 women and four men. Hip joint measurements were made on preoperaive standard x-rays with complementary recentered views if needed as well as computed tomography (CT) to better distinguish progressive degeneration. For early patients, the iniail osteotomy involved three cuts (ilioischial, iliopubic, ilial) starting close to the acetabulum and performed via three approaches: sub coxofemoral, intrapelvic, extrapelvic. The first technical change involved osteotomy of the anterosuperior iliac spine and an oblique iliac cut farther from the acetabulum.

Results: Mean preoperative angles were: 135° (121 to 150°) for CC’D, 23.2° (3 to 40°) for HTE, 8.4° (−14 to 22°) VCE, 11.3° (−26 to 32°) for VCA. The postoperative values were: 134.5° (121 to 150°) for CC’D, 9.5° (−9 to 20°) for HTE, 31.7° (14 to 60°) for VCE, 31.7° (10 to 48°) for VCA. Six patients required total hip arthroplasty on average four years later (range 2 – 9 years), including one patient with aseptic necrosis of the acetabulum.

Discussion and Conclusion: This study confirms the usefulness of triple periacetabular osteotomy for conservative treatment of acetabular dysplasia. In light of our results, the following changes have been instituted:

1. all three cuts are performed via a single intra-pelvic approach;

2. For severe extreme dysplasia (Hip Study Group classification), a two-thirds triple osteotomy is performed (original technique). Currently the best indication appears to be a young patient (less than 30 years) with moderate to severe dysplasia, without intra-articular suffering and without any sign of early stage joint degradation.